title: Hedgehog Pathway Inhibition.
abstract: The hedgehog (Hh) signaling pathway is aberrantly activated in a majority of basal cell carcinomas (BCC). Vismodegib and sonidegib are targeted inhibitors of Smoothened (SMO). Both drugs are approved for use in locally advanced BCC (laBCC), with vismodegib also approved for metastatic BCC (mBCC).
authors.affiliation: Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA. Electronic address: sekulic@mayo.edu.
authors.forename: Aleksandar
authors.initials: A
authors.lastname: Sekulic
authors.affiliation: Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA.
authors.forename: Daniel
authors.initials: D
authors.lastname: Von Hoff
mesh_terms: D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001713:Biphenyl Compounds / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy*; D053823:Hedgehog Proteins / Q000378:metabolism*; D006801:Humans; D011725:Pyridines / Q000627:therapeutic use*; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*; D012878:Skin Neoplasms / Q000188:drug therapy*; D000072086:Smoothened Receptor; D057170:Translational Research, Biomedical
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; D001713:Biphenyl Compounds; D053823:Hedgehog Proteins; C538724:HhAntag691; D011725:Pyridines; D043562:Receptors, G-Protein-Coupled; C491023:SMO protein, human; D000072086:Smoothened Receptor; C561435:sonidegib